A body signal changes how brain tumor cells die in lab tests
Original title: High-throughput spheroid profiling reveals BMP-driven rewiring of glioma cell death responses.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done in tumor cells grown in a dish.
The short version
In lab dishes, one signal made brain tumor cells resist some drugs but open to another kind of death.
What was studied. Scientists built a fast way to test cell death in tiny balls of tumor cells. The cells came from people with glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary and with DIPG. The team checked how signals from outside the cell changed the effect of drugs.
What they found. Two signals, called BMP2 and BMP4, changed how the cells died. They blocked the killing done by standard chemo drugs and by targeted drugs called kinase inhibitors. They did this by stopping the cells from dividing. At the same time, they set the cells up for a different kind of death that depends on fat. A drug candidate called tegavivint could set off that death. Changes in a receptor called ACVR1, found in about 25% of DIPG tumors, did the same thing on their own.
What this means, and what it doesn't
What it could mean: This is early lab work. It may help explain why some tumors shrug off chemo. It also points to a second way these cells can be killed. A doctor cannot offer any of this today.
What it doesn't mean: This does not mean a new treatment is ready. The work was done in tumor cells grown in a dish, not in people. Tegavivint is still only a drug candidate, not an approved brain tumor drug. This is not a cure, and it is a long way from everyday care.
Source: PubMed, September 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.